At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 218 enrolled
Drug / intervention
[18F] Flutemetamoldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-arm, Open-label, Multi-center Study to Determine the Specificity of Flutemetamol (18F) Injection for Excluding the Presence of Brain Amyloid in Healthy Young Adult Subjects Aged 18 to 40
In Brief
A Phase 3 clinical trial evaluating [18F] Flutemetamol for Healthy. Completed, enrolled 218 participants across 1 site.
Detailed Summary
Amyloid is an abnormal chemical found in the brain of patients with Alzheimer's Disease (AD). The study drug helps produce pictures of amyloid in the brain. The purpose of this study is to determine how well the study drug performs in young healthy subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaboratorsi3 Statprobe, Medpace, Inc.
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2010
First PostedDec 2010
Primary CompletionMar 2011
Study CompletionApr 2011
TodayJul 2026
First PostedDec 23, 2010
Enrollment StartDec 1, 2010
Primary CompletionMar 1, 2011
Study CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 15.5 years ago
Interventions
[18F] Flutemetamoldrug
Flutemetamol (18F) Injection, 185 MBq/5 mCi, single intravenous injection.